Figure 3.

Independent studies highlight convergent conclusions in acetate utilisation in HCC heterogeneity. Separate investigations associated increased expression of ACSS1 with poor survival outcome. A, Stratification of tumours based on ACSS1 and ACSS2 expression led to the identification of poor prognosis markers in tumours expressing ACSS1 at a high level [6]. B, Clustering of tumours on the basis of fGGN and transcriptomic data resulted in the characterisation of three HCC subtypes, of which the subtype conferring the least favourable survival was found to preferentially express ACSS1 for acetate utilisation [56].